Maxele Advisors LLC Acquires New Holdings in iShares Biotechnology ETF $IBB

Maxele Advisors LLC bought a new position in iShares Biotechnology ETF (NASDAQ:IBB) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 4,670 shares of the financial services provider’s stock, valued at approximately $674,000.

Other large investors have also added to or reduced their stakes in the company. BNP Paribas Financial Markets grew its holdings in shares of iShares Biotechnology ETF by 313.2% in the third quarter. BNP Paribas Financial Markets now owns 1,915,395 shares of the financial services provider’s stock worth $276,526,000 after acquiring an additional 1,451,820 shares during the period. Citigroup Inc. lifted its holdings in iShares Biotechnology ETF by 27.0% in the second quarter. Citigroup Inc. now owns 4,073,967 shares of the financial services provider’s stock valued at $515,398,000 after acquiring an additional 865,823 shares during the period. Jefferies Financial Group Inc. bought a new position in iShares Biotechnology ETF in the third quarter valued at about $65,083,000. JPMorgan Chase & Co. boosted its position in iShares Biotechnology ETF by 74.2% in the second quarter. JPMorgan Chase & Co. now owns 833,196 shares of the financial services provider’s stock worth $105,408,000 after purchasing an additional 355,000 shares during the last quarter. Finally, Employees Retirement System of Texas purchased a new position in iShares Biotechnology ETF in the second quarter worth about $25,049,000. Institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Performance

iShares Biotechnology ETF stock opened at $167.14 on Tuesday. iShares Biotechnology ETF has a 52-week low of $107.43 and a 52-week high of $179.64. The business has a 50-day simple moving average of $172.68 and a two-hundred day simple moving average of $162.92.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.